Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Recruiting 7Withdrawn 3Unknown 3Completed 3Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 2Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × sotorasib × Clear all
NCT06068153 2024-11-20

AMBER

ETOP IBCSG Partners Foundation

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05815186 2024-03-29

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NYU Langone Health

Phase 2 Withdrawn
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT05400577 2023-07-17

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Fox Chase Cancer Center

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡